

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-46. (Cancelled)

47. (Currently Amended): A method of reducing the reactogenicity of QS21 containing adjuvant formulations, wherein the QS21 is present in substantially purified form, by the addition of excess sterol to the adjuvant formulation (~~weight/weight~~) weight/weight (w/w).

48. (Currently Amended): A method of stabilising QS21 against alkali mediated hydrolysis in QS21 containing adjuvant formulations, wherein the QS21 is present in substantially purified form, by the addition of excess sterol to the adjuvant formulation (~~weight/weight~~) weight/weight (w/w).

49. (Cancelled)

50. (New): A method according to claim 47 wherein the ratio of QS21 to sterol in the formulation is from 1:100 to 1:1 w/w.

51. (New) : A method according to claim 48 wherein the ratio of QS21 to sterol in the formulation is from 1:100 to 1:1 w/w.

52. (New): A method according to claim 47 wherein the ratio of QS21 to sterol in the formulation is at least 1:2 w/w.

53. (New) A method according to claim 48 wherein the ratio of QS21 to sterol in the formulation is at least 1:2 w/w.

54. (New) A method according to claim 47 wherein the ratio of QS21 to sterol in the formulation is 1:5 w/w.

55. (New) A method according to claim 48 wherein the ratio of QS21 to sterol in the formulation is 1:5 w/w.

56. (New): A method according to claim 47 wherein the sterol is cholesterol.

57. (New): A method according to claim 48 wherein the sterol is cholesterol.

58. (New): A method according to claim 50 wherein the sterol is cholesterol.

59. (New): A method according to claim 51 wherein the sterol is cholesterol.

60. (New): A method according to claim 52 or 54 wherein the sterol is cholesterol.

61. (New): A method according to claim 53 or 55 wherein the sterol is cholesterol.

62. (New): A method according to claim 47 wherein the adjuvant formulation also contains 3D-MPL.

63. (New): A method according to claim 48 wherein the adjuvant formulation also contains 3D-MPL.

64. (New): A method according to claim 47 wherein the QS21 and the sterol are comprised in a vesicle-like structure.

65. (New): A method according to claim 48 wherein the QS21 and the sterol are comprised in a vesicle-like structure.

66. (New): A method according to claim 64 wherein the formulation contains lipid which, together with the QS21 and the sterol, forms small unilamellar liposomes.

67. (New): A method according to claim 65 wherein the formulation contains lipid which, together with the QS21 and the sterol, forms small unilamellar liposomes.

68. (New): A method according to claim 66 wherein the formulation also contains alum salts.

69. (New): A method according to claim 67 wherein the formulation also contains alum salts.

70. (New): A method according to claim 66 wherein the adjuvant formulation also contains 3D-MPL.

71. (New): A method according to claim 67 wherein the adjuvant formulation also contains 3D-MPL.

72. (New): A method according to claim 50 wherein the formulation also contains alum salts.

73. (New): A method according to claim 51 wherein the formulation also contains alum salts.